Executive Summary

The Indian Pharmaceutical Market (IPM) sustained its growth trajectory in early 2026, recording 11.0% year-on-year (YoY) growth in February 2026, with monthly sales reaching ₹20,836 crore. The Moving Annual Total (MAT) stood at ₹2,44,277 crore, reflecting 8.4% annual growth.

Growth remained broad-based across all three levers—price (+5.3%), new product introductions (+3.5%), and volume (+2.2%)—with a notable improvement in volume growth indicating gradual recovery in prescription demand.

The market continues to structurally shift toward chronic care. Chronic and sub-chronic therapies now account for 56% of IPM value, up from 53% in 2022, reflecting the rising burden of non-communicable diseases (NCDs).

Within this broader transition, GLP-1 receptor agonists are emerging as a significant new growth driver, with expanding clinical adoption and an evolving competitive landscape.

Part I: Market Overview and Therapy Dynamics

1.1 Overall Market Performance (February 2026)

Source: Pharmarack Technologies, March 2026
Note: Growth rates refer to February YoY unless specified

1.2 Segment Shift: Acute to Chronic

Chronic therapies continue to outpace acute segments, supported by rising incidence of diabetes, cardiovascular disease, and other lifestyle-related conditions.

1.3 Therapy-Level Performance

Sources: IQVIA, Pharmarack

1.4 Growth Quality

• Vaccines led value growth (24.4%) and unit expansion (32.3%) in January 2026
• Select therapy groups (GI, vitamins, pain) showed unit softness, indicating selective demand pressure
• Overall growth remains value-led but gradually normalizing toward volume contribution

Part II: GLP-1 Therapies — A Structural Inflection Point

2.1 Market Scale and Momentum

The GLP-1 receptor agonist segment has rapidly scaled into a meaningful specialty category within the IPM. The combined market for semaglutide and tirzepatide is estimated at over ₹1,500 crore as of February 2026, with strong year-on-year expansion.

Source: PharmaTrac (Feb 2026 estimates)

Certain brands within this category have demonstrated exceptionally rapid scale-up, positioning them among the fastest-growing therapies in recent IPM history.

2.2 Competitive Dynamics

Recent pricing and access strategies have accelerated semaglutide adoption:

• Price adjustments improved affordability
• Expanded partnerships enhanced distribution reach
• Increased physician familiarity supported onboarding

This has translated into incremental patient additions, particularly in urban and specialist-led markets.

2.3 Patent Expiry and Market Expansion

The expiry of semaglutide patents in India (March 2026) is expected to reshape the competitive landscape.

• 40+ companies preparing entry
• 50+ brands anticipated over the next 12–18 months
• Increased participation from domestic manufacturers

Pricing Outlook:
Industry expectations suggest that monthly therapy costs could decline to the ₹3,000–5,000 range, subject to competitive intensity and regulatory dynamics.

2.4 Patient Access and Adoption Potential

While only a small fraction of patients are currently treated, a broader subset of individuals with obesity and uncontrolled diabetes may become eligible over time, contingent on affordability, physician adoption, and long-term adherence.

2.5 Regional Adoption Trends

2.6 Risks and Adoption Constraints

Despite strong momentum, several factors may moderate adoption:

• Adherence challenges: Gastrointestinal side effects and discontinuation rates
• Affordability: Even post-generic pricing may remain high for long-term therapy
• Supply constraints: Global demand pressures affecting availability
• Physician adoption curve: Gradual expansion beyond specialists
• Lifestyle factors: Diet, alcohol consumption, and compliance influencing outcomes

These factors suggest that market expansion will likely be progressive rather than exponential.

Part III: Corporate Landscape

3.1 Therapy Leadership

3.2 Strategic Priorities

Companies are balancing:

• Chronic portfolio expansion
• Lifecycle management of legacy brands
• Partnerships and licensing
• Leveraging off-patent opportunities

Acute therapies remain relevant, contributing 44% of total IPM value, particularly in seasonal cycles.

Part IV: Geographic Trends

4.1 Zonal Performance (MAT)

4.2 Metro Growth

• Top 30 metros grew 12.3%, outperforming MAT growth (~9–10%)
• Mumbai, Hyderabad, Bangalore among leading growth markets

Part V: Outlook for 2026

5.1 Growth Expectations

Pharmarack projects 7.8–8.1% IPM growth for 2026, with:

5.2 Key Themes

1. Shift toward volume-led growth
2. Expansion of chronic therapies
3. Increased access through generics
4. Gradual channel diversification (still largely physician-led)

Conclusion

The Indian pharmaceutical market continues to demonstrate structural resilience, supported by chronic disease prevalence and steady demand expansion.

GLP-1 therapies represent a high-impact emerging segment, with the potential to expand treatment paradigms in diabetes and obesity. However, adoption will likely depend on affordability, adherence, and clinical positioning, rather than price alone.

As the market evolves, companies that align portfolios with chronic care trends, leverage post-patent opportunities, and execute effectively across channels will be best positioned to capture growth.

Appendix: Sources and Data Validation

All Images are AI Generated for Illustration Only. E&OE